Commentary

You have full text access to this OnlineOpen article

Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?†‡

  1. Glen M Blake1,*,
  2. Juliet E Compston2,
  3. Ignac Fogelman1

Article first published online: 15 JUN 2009

DOI: 10.1359/jbmr.090601

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 24, Issue 8, pages 1354–1357, August 2009

Additional Information

How to Cite

Blake, G. M., Compston, J. E. and Fogelman, I. (2009), Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?. J Bone Miner Res, 24: 1354–1357. doi: 10.1359/jbmr.090601

Author Information

  1. 1

    King's College London School of Medicine, London, United Kingdom

  2. 2

    University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom

*Address correspondence to: G. M. Blake, PhD, Osteoporosis Research Unit, 1st Floor, Tower Wing, Guy's Hospital, London SE1 9RT, UK

  1. †

    The authors state that they have no conflicts of interest

  2. ‡

    Published online on June 15, 2009

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 15 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (436K)

REFERENCES

  • 1
    Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, de la Pena MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J 2009 Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24: 1358–1368.
    Direct Link:
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535–1541.
  • 3
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 2077–2082.
  • 4
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282: 1344–1352.
  • 5
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomised clinical trial. JAMA 282: 637–645.
  • 6
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y 2001 Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med 344: 333–340.
  • 7
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Milak BH 2001 Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344: 1434–1441.
  • 8
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249.
    Direct Link:
  • 9
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–468.
  • 10
    Reginster J-Y, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemarere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90: 2816–2822.
  • 11
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
  • 12
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762–1768.
  • 13
    Boivin G, Meunier PJ 2002 Effects of bisphosphonates on matrix mineralisation. J Musculoskelet Neuronal Interact 2: 538–543.
  • 14
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 112: 281–289.
  • 15
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051–1056.
    Direct Link:
  • 16
    Compston JE 2007 Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. Bone 40: 1447–1452.
  • 17
    Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y 1993 An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8: 607–615.
    Direct Link:
  • 18
    Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18: 517–523.
  • 19
    Marie PJ, Ammann P, Boivin G, Rey C 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69: 121–129.
  • 20
    Marie PJ 2005 Strontium ranelate: A novel mode of action optimizing bone formation and bone resorption. Osteoporos Int 16 (Suppl 1): S7–S10.
  • 21
    Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB 2008 Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19: 1331–1341.
  • 22
    Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C 2002 Prevention of early postmenopausal bone loss by strontium ranelate: The randomised, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos Int 13: 925–931.
  • 23
    Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Neilsen S, de Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomised placebo controlled trial. J Clin Endocrinol Metab 87: 2060–2066.
  • 24
    Brixen K, Krogsggaard K, Chritsgau S, Weis M, Eastell R 2008 Effect of three doses of strontium malonate (NB S101) on markers of bone turnover: The STRONG study. Calcif Tissue Int 82 (Suppl 1): S217.
  • 25
    Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ 2008 Histomorpometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23: 215–222.
    Direct Link:
  • 26
    Farley D, Boivin G, Panczer G, Lalande A, Meunier PJ 2005 Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 20: 1569–1578.
    Direct Link:
  • 27
    Pors Nielsen S, Slosman D, Sorensen OH, Basse-Cathelinat B, De Casin P, Roux C, Meunier PJ 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual x-ray absorptiometry. J Clin Densitom 2: 371–379.
  • 28
    Blake GM, Fogelman I 2006 Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Miner Res 21: 1417–1424.
    Direct Link:
  • 29
    Boivin G, Farley D, Simi C, Meunier PJ 2006 Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int 17 (Suppl 2): S210.
  • 30
    Blake GM, Fogelman I 2007 The correction of BMD measurements for bone strontium content. J Clin Densitom 10: 259–265.
  • 31
    Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R 2007 Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22: 1419–1425.
    Direct Link:
  • 32
    Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92: 3076–3081.
  • 33
    Ortolani S, Diaz-Curiel M 2006 Strontium ranelate: Changes in BMD one year after treatment discontinuation. J Bone Miner Res 21: S1; S189.
  • 34
    Blake GM, Lewiecki EM, Kendler DL, Fogelman I 2007 A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10: 113–119.
  • 35
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207–1215.
  • 36
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745–751.
    Direct Link:
  • 37
    Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93: 852–860.
  • 38
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555–565.
  • 39
    Boivin GY, Chavassieux PM, Santora A, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687–694.
View Full Article (HTML) Get PDF (436K)